Primary Disease Clinical Trial
Official title:
Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons Between Non-viral and Viral Administration in Tissue Engineered Bone Regeneration
The first year purpose:
The best concentration of canonical Wnt3a will be investigated in promoting the
osteoblastogenesis of human mesenchymal stem cells.
Our previous work is investigating the viral (Adv-BMP-2) administration for the development
of a model to generate bones for possible use in clinical settings; the non-viral and viral
administrations will be compared for best osteogenesis effects.
The first year purpose:
The best concentration of canonical Wnt3a will be investigated in promoting the
osteoblastogenesis of human mesenchymal stem cells.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03702361 -
Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease
|
Phase 4 | |
| Completed |
NCT00405210 -
Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer
|
Phase 1 | |
| Completed |
NCT01325194 -
CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis
|
Phase 2 | |
| Completed |
NCT00803244 -
Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis (With or Without Asthma)
|
Phase 3 | |
| Completed |
NCT01214798 -
A Case of Sesamoid Displacement Causing the First Metacarpophalangeal Joint Locking
|
N/A | |
| Completed |
NCT00552461 -
Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
|
Phase 2 | |
| Terminated |
NCT01868243 -
Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively
|
Phase 2/Phase 3 |